Floatz logo

(+)-VINCRISTINE

Anaplastic Astrocytoma

Novartis PharmaceuticalsSmall moleculePhase 2/3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
81/ 100

Competitive context

36 Active assets in the Anaplastic Astrocytoma cohort.

Asset / SponsorPhaseRating
Cediranib
National Cancer Institute (NCI)
Phase 2BBB
Irinotecan
City of Hope Medical Center
Phase 2/3BBB
Carboplatin
Oliver Jonas
Phase 2BB
gsk1120212
National Cancer Institute (NCI)
Phase 4BB
Cintredekin Besudotox
INSYS Therapeutics Inc
Phase 1/2BB

View all 50 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →